CA-62 Reagent Set for Early Epithelial Carcinoma Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer markers lack sensitivity and specificity for early-stage detection, leading to delayed diagnosis and increased mortality, and existing methods for monitoring treatment response are costly and invasive.
Innovation Solution
A diagnostic test using monoclonal antibodies against the N-glycoprotein CA-62, combined with a chemiluminescence immunoassay, for detecting early stages of epithelial carcinomas and monitoring treatment response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer markers (PSA, CEA, CA-125) are used for early cancer detection, then the diagnostic method is widely available and simple, but the sensitivity and specificity are insufficient leading to false negative results
Solution Approach 1:
The patent introduces a new biomarker parameter (CA-62 N-glycoprotein) with different characteristics from conventional markers. This marker shows maximum expression at the very beginning of cancer development, unlike traditional markers that are more prominent in later stages. By changing the measured parameter from conventional markers to CA-62, the test achieves 95% sensitivity and 90% specificity for early-stage epithelial carcinomas
Solution Approach 2:
The diagnostic system combines multiple components: CA-62 N-glycoprotein biomarker, monoclonal antibodies specific to CA-62, and chemiluminescence detection technology. This composite approach integrates a novel biomarker with advanced detection methods to achieve superior diagnostic performance compared to single-marker systems
2Productivity
If conventional cancer markers are used for screening, then the screening programs are broadly implemented, but false positive results lead to overdiagnosis and increased invasive procedures
Solution Approach 1:
By switching from conventional markers (PSA, CEA, CA-125) to the CA-62 marker, the patent achieves higher specificity (90%) for early-stage cancer detection. This parameter change reduces false positive results that lead to unnecessary biopsies and overdiagnosis, particularly in prostate cancer screening where conventional markers cause significant harm
3Measurement precision
If invasive diagnostic procedures like biopsy are performed to confirm cancer diagnosis, then accurate diagnosis can be obtained, but severe complications occur in approximately 30% of cases
Solution Approach 1:
The patent uses CA-62 N-glycoprotein as an intermediary biomarker that provides accurate cancer detection information without requiring direct tissue sampling. This blood-based marker serves as a non-invasive mediator between the tumor and the diagnostic test, eliminating the need for invasive biopsies in many cases while maintaining high diagnostic accuracy
Solution Approach 2:
The patent replaces the mechanical invasive procedure of biopsy with a biochemical test measuring CA-62 levels in blood. This substitution eliminates physical trauma to the patient while providing equivalent or superior diagnostic information about early-stage cancer presence
4Productivity
If conventional cancer markers are used for monitoring treatment response, then the monitoring can be performed, but the cost is high and the methods are invasive
Solution Approach 1:
The CA-62 biomarker serves as a non-invasive intermediary for monitoring treatment response and cancer recurrence. By measuring CA-62 levels in blood samples, the system provides continuous monitoring capability without requiring invasive procedures or expensive specialized equipment, making treatment follow-up accessible and affordable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The test achieves high sensitivity (80-95%) and specificity (80-95%) for early cancer detection and treatment monitoring, reducing false positives and negatives, and providing timely intervention.
Implementation Method 1
A novel diagnostic test for the detection of the marker for epithelial carcinomas allows identification of the novel biomarker, cancer-associated N-glycoprotein CA-62 from the surface of epithelial cancer cells in the patients' serum
Implementation Method 2
A diagnostic test using monoclonal antibodies against the N-glycoprotein CA-62, combined with a chemiluminescence immunoassay, for detecting early stages of epithelial carcinomas
Data Source
AI summary
Laboratory cancer diagnostics are disclosed. A set of reagents for detecting the marker for epithelial carcinomas CA-62 in patients' blood serum for early detection of cancer, detecting cancer recurrences and monitoring cancer treatment of human epithelial tumors using immunochemical analysis, is described. A difference between the CA-62 cancer marker and other well-known markers relates to the maximum peak of its expression failing on the very beginning of cancer development. This makes it possible to detect early stages of tumor growth with high sensitivity and specificity when the cure rate is at maximum. The dynamics of the CA-62 marker level show high efficacy in detecting tumor recurrences and monitoring the treatment of patients with advanced cancer. The set of reagents includes a microplate with immobilized antibodies to a CA-62 cancer antigen, CA-62-Acridinium conjugate, CA-62 standard calibrators from 10-30000 U/ml, CA-62 positive control, working buffer solution (pH 2.0-8.0) containing Tween-80.